Amgen Stock Soars 6.7% on Repatha Expansion Approval
Amgen's stock price has risen by 6.7% after the European Medicines Agency (EMA) gave its backing to expand Repatha's use in high-risk patients. This decision is based on Phase 3 VESALIUS-CV data, which showed meaningful reductions in first major cardiovascular events and LDL-C levels.
The expanded use of Repatha for high-risk cardiovascular prevention could broaden the eligible patient pool and reinforce Amgen's position in treating primary prevention populations. However, this does not fundamentally change the near-term risk that higher investment and pricing pressure could squeeze margins.
Amgen's recent Q2 2026 results showed solid reported revenue of $10,054 million and net income of $2,375 million, demonstrating how existing products contribute to earnings power that funds ongoing cardiovascular trials and potential indication expansions. The company projects $41.5 billion in revenue and $10.3 billion in earnings by 2029.